Sight Sciences, Inc. ( (SGHT) ) has released its Q4 earnings. Here is a breakdown of the information Sight Sciences, Inc. presented to its investors.
Sight Sciences, Inc. is an eyecare technology company that focuses on developing and commercializing innovative interventional technologies to improve patient care in the field of ophthalmology. The company is known for its minimally invasive solutions for glaucoma and dry eye disease.
In its latest earnings report, Sight Sciences announced a slight increase in fourth-quarter revenue to $19.1 million, marking a 2% rise from the previous year. However, the full-year revenue for 2024 saw a minor decline of 1% compared to 2023, totaling $79.9 million. The company also initiated its financial guidance for 2025.
Key financial highlights include a gross margin of 87% in the fourth quarter, an improvement from the previous year, and a significant reduction in cash usage by 62% for the year. The company also reported a net loss of $11.8 million for the fourth quarter and $51.5 million for the full year, showing a slight improvement from the previous year’s losses.
Sight Sciences is focusing on strategic initiatives for 2025, including advancing its market presence in minimally invasive glaucoma surgery (MIGS) and expanding access to its TearCare System for dry eye treatment. The company plans to release a next-generation OMNI Surgical System in the first half of 2025.
Looking ahead, Sight Sciences anticipates a revenue decline in 2025 due to changes in Medicare coverage affecting the MIGS market. The company remains committed to its strategic goals and aims to enhance its product offerings and market access in the coming year.